Plain-English translation of NCT07222488 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new medication called to treat high-risk, early-stage bladder cancer after surgery. Researchers want to learn whether this medication is safe and well-tolerated when placed directly into the bladder. The goal is to help prevent cancer from returning or spreading.
Currently, doctors treat early-stage bladder cancer with surgery followed by a standard medication called BCG. However, this treatment doesn't work for everyone, and some people experience side effects or their cancer comes back. This study is exploring whether this new treatment could be a better option for patients who haven't responded to BCG or who can't tolerate it.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the medication injected directly into your bladder once a week for 6 weeks, then once a month for 9 months. You'll need to hold the medication in your bladder for 1–2 hours before urinating. The study will last about one year, and you'll have regular visits to monitor how well you tolerate the treatment and whether it's working to prevent cancer from returning.
AI-generated summary from trial data · Sep 3, 2026 · Not medical advice
United States
Austria